CatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug Conjugates at AACR 2025
Preclinical in vitro and in vivo data show enhanced anti-tumor activity when combining visugromab, a GDF-15-neutralizing antibody candidate, with approved antibody-drug-conjugate (ADC) treatment GDF-15 blockade enhances ADC activity, immune cell infiltration, and activation in the tumor Findings support continued investigation of GDF-15 neutralization as a potential strategy to overcome cancer therapy resistance for a variety of treatment modalities CatalYm today […]
Bioqube Ventures Appoints Tom Heyman as Executive Partner
Bioqube Ventures, an emerging life sciences investment firm, is pleased to announce the appointment of Tom Heyman as Executive Partner, joining the firm’s leadership team. Tom Heyman is a seasoned pharma executive with more than 40 years of experience in general management, business development, and equity investments. He spent his entire career at Johnson & Johnson […]
CatalYm Announces Leadership Changes to Accelerate Visugromab Late-stage Clinical Development
Experienced executives, Clinton Musil, Sujata Rao, MD, Heike Krupka, PhD, and Andrea Goddard join CatalYm to broaden and accelerate clinical programs into late-stage development CatalYm , a world-leader in neutralizing GDF-15 in cancer and cachexia, today announced changes to its executive leadership team to support its next stage of growth. The appointments of Clinton Musil as […]
Spica Therapeutics Secures €1 Million VLAIO Grant to Advance Groundbreaking Macrophage-Targeted Cancer Therapy
Spica Therapeutics, a pioneering biotech company focused on harnessing macrophage biology to develop transformative therapies across multiple disease areas, announced today that it has been awarded a €1.0 million grant from Flanders Innovation & Entrepreneurship (VLAIO). This two-year grant will accelerate the development of Spica’s lead anti-CD163 depleting monoclonal antibody program in oncology, propelling it toward […]
SynOx Therapeutics Completes Enrollment in Registrational Phase 3 TANGENT Clinical Trial Significantly Ahead of Timeline
Top-Line Results from Study Evaluating Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT) Expected in First Quarter of 2026 SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced completion of patient enrolment in the TANGENT study. TANGENT is the company’s a global, multi-centre, randomized, double-blind, placebo-controlled […]
Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy
Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndicate including Bioqube Ventures, Surveyor Capital and others Led by founder and drug discovery expert Dr. Andreas Goutopoulos, Actithera’s proprietary three- pillar discovery platform is designed to enable prolonged radioligand tumor retention Proceeds will support […]
Egle Therapeutics to Present New Preclinical Data EGL-003, a Novel IL-2 Mutein for Selective Expansion of Tregs to Restore Immune Balance with Best-in-class Potential, at EULAR 2025 Congress
Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced a poster presentation at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is being held from June 11-14, 2025, at Fira de Barcelona in Barcelona, Spain. The poster will feature new […]
Commit Biologics appoints leading industry experts to newly formed Scientific Advisory Board
Industry and scientific experts in molecular biology, immunology and antibody research appointed to help develop Commit’s BiCE™ technology platform to treat autoimmune disease and cancer Leading antibody expert Janine Schuurman to co-chair Commit’s Scientific Advisory Board alongside Commit’s CEO Mikkel Wandahl Pedersen Joined by Paul Parren, Gavin Thurston, Susan Kalled, and Esper Boel on the […]
Spica Therapeutics Closes €10 Million Seed Round to Advance Macrophage-Targeted Therapies
The financing round was co-led by Bioqube Ventures and Flanders Future Tech Fund (FFTF, managed by the Flemish investment company PMV), with participation from Qbic. Spica entered a strategic collaboration with Vrije Universiteit Brussel (VUB) and VIB, a leading life sciences research institute to leverage world-class expertise across Belgium. The funding will enable the company […]
Egle Therapeutics to Present Clinical Trial Progress Poster on Phase I/II EGL-121 Study for EGL-001 at 2025 ASCO Annual Meeting
Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced a poster presentation at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held from May 30 to June 3, 2025, at the McCormick Place in Chicago, IL. The poster […]